CCM
PRME icon

CAAS Capital Management’s Prime Medicine PRME Stock Holding History

CAAS Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-89,331
Closed -$1.66M – 864
2022
Q4 		$1.66M Buy
+89,331
New +$1.61M 0.1% 219

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAAS Capital Management's PRME Position: Q1 2023 in Review

CAAS Capital Management sold out of Prime Medicine (PRME) in Q1 2023, closing a stake of 89,331 shares — an estimated $1.66M sold.

CAAS Capital Management first reported a position in PRME in Q4 2022 and held it in 1 quarter. The position peaked at $1.66M in Q4 2022. 76 funds tracked by Wall St. Rank hold PRME as of Q1 2023.

  • CAAS Capital Management reported no remaining Prime Medicine position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 89,331 Prime Medicine shares in Q1 2023, an estimated $1.66M.
  • CAAS Capital Management first reported a position in Prime Medicine in Q4 2022 and held it in 1 quarter.
  • CAAS Capital Management's Prime Medicine position peaked at $1.66M in Q4 2022.
  • 76 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.